Danish Novo Nordisk launched its blockbuster treatment injection Ozempic in three forms in 0.25 mg, 0.5 mg and 1 mg in the ...
Ozempic, a GLP-1 receptor agonist, has officially launched in India, offering a new treatment option for type 2 diabetes.
Blockbuster semaglutide injection offered in weekly FlexTouch pens; firm says pricing kept ‘competitive’ for India ...
Novo Nordisk’s blockbuster diabetes drug, Ozempic, was officially launched in India on December 12. Unlike in the US and ...
With India facing over 101 million cases of diabetes and rising obesity levels, the drug could play a significant role in ...